Santwana Padhi

14 papers receiving 828 citations

Hit Papers

Type II diabetes mellitus: a review on recent drug based ...20202026202220242020100200300400

Peers

Santwana Padhi
Comparison fields: 5 of 115
  • Molecular Biology 305
  • Endocrinology, Diabetes and Metabolism 207
  • Biomaterials 156
  • Pharmaceutical Science 131
  • Biomedical Engineering 114
Replace Ashwini Kumar with:
Ashwini Kumar India
Florin Borcan Romania
Yanting Huang China
Sharuk L. Khan India
Aakash Deep India
D.N. Prasad India
Talat Roome Pakistan
Joana R. Campos Portugal
Md. Faiyazuddin India
Fakhria A. Al‐Joufi Saudi Arabia
Santwana Padhi relative to Ashwini Kumar India Ashwini Kumar's profile →
Citations per field
00.5×1.5×2.2×
Ashwini Kumar · 1×
Citations per year

Countries citing papers authored by Santwana Padhi

Since Specialization
Citations

This map shows the geographic impact of Santwana Padhi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Santwana Padhi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Santwana Padhi more than expected).

Fields of papers citing papers by Santwana Padhi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Santwana Padhi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Santwana Padhi. The network helps show where Santwana Padhi may publish in the future.

Co-authorship network of co-authors of Santwana Padhi

This figure shows the co-authorship network connecting the top 25 collaborators of Santwana Padhi. A scholar is included among the top collaborators of Santwana Padhi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Santwana Padhi. Santwana Padhi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
#WorkIndexed citations
1 0
2 2
3 2
4 19
5 17
6 6
7 61
8 23
9 9
10
Type II diabetes mellitus: a review on recent drug based therapeuticsbreakdown →
430
11 94
12 29
13 45
14 31
15 75

About Santwana Padhi

Santwana Padhi is a scholar working on Biomaterials, Pharmaceutical Science and Microbiology, having authored 15 papers that have together received 843 indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (6 papers), Cancer therapeutics and mechanisms (4 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). The work is most often cited by research in Pharmaceutical Science (131 citations), Endocrinology, Diabetes and Metabolism (207 citations) and Biomaterials (156 citations). Santwana Padhi has collaborated with scholars based in India, Malaysia and South Korea. Frequent co-authors include Anindita Behera, Amit Kumar Nayak, Devina Verma, Tahir Khuroo, Sushama Talegaonkar, Amulya K. Panda, Zeenat Iqbal, Zeenat Iqbal, Hira Choudhury and Shadab Md. Their work appears in journals such as International Journal of Pharmaceutics, Journal of Molecular Liquids and European Journal of Pharmaceutics and Biopharmaceutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026